CDSCO (India)

CDSCO (Central Drugs Standard Control Organization) is the central regulatory authority for drugs, cosmetics + medical devices in India, under the Ministry of Health and Family Welfare. CDSCO is headed by the Drugs Controller General of India (DCGI) — a senior position with delegated statutory authority under the Drugs and Cosmetics Act 1940. CDSCO's national headquarters is in New Delhi, with Zonal + Sub-Zonal + Port Offices distributed across India + integrated with the SUGAM online portal that operates virtually all submissions + licensing transactions.

The CDSCO ecosystem includes:

• CDSCO HQ + Zonal / Sub-Zonal / Port Offices — central + regional regulatory operations.
• DCGI — the Drugs Controller General of India + the office of the DCGI with technical + administrative staff.
• Indian Pharmacopoeia Commission (IPC, Ghaziabad) — the national pharmacopoeial authority + the publisher of the Indian Pharmacopoeia (IP), the legal compendium for drugs in India.
• Central Drugs Laboratory (CDL Kolkata) — the apex national drug-testing laboratory + the appellate analytical authority.
• National Institute of Biologicals (NIB Noida) — central reference laboratory for biologicals, vaccines + blood products; lot release for vaccines.
• CDSCO Medical Devices + Diagnostics Division — central authority for Class C + D devices + import + new-device assessments.
• State Licensing Authorities (SLAs) — under each state's Drugs Control Department; handle manufacturing licences for older drugs + Class A + B devices + retail + wholesale + day-to-day enforcement.
• Pharmacovigilance Programme of India (PvPI) — the national pharmacovigilance programme operated by IPC + the AMC (ADR Monitoring Centre) network.

The Indian regulatory architecture is federal-state dual: CDSCO at the central level + SLAs at the state level. This split has substantial operational implications: a manufacturer might hold a CDSCO import licence + a state SLA manufacturing licence + multiple state SLA retail / wholesale licences, with different inspection authorities + sometimes different interpretations across states.

Legal foundations are the Drugs and Cosmetics Act 1940 + Drugs and Cosmetics Rules 1945 (the foundational statutory framework, with Schedule M defining GMP), the New Drugs and Clinical Trials Rules 2019 (the modernised clinical-trial + new-drug framework that consolidated multiple earlier rules), the Medical Devices Rules 2017 + Feb 2020 amendment (the framework that progressively brought ALL devices under regulation, in phased risk-based licensing), the Cosmetics Rules 2020, the Pharmacy Act 1948 + state pharmacy councils, and a substantial body of CDSCO Guidance documents.

CDSCO is an ICMRA member, an ICH observer working toward Regulatory Membership, a PIC/S applicant + active observer, an active IMDRF participant, and has achieved WHO ML3 maturity for vaccines in 2017 + ML4 in 2024 for selected functions — a critical enabler for Indian vaccine WHO Prequalification + global supply.

Understanding the CDSCO + SLA split is essential for any company operating in India. The Drugs and Cosmetics Act 1940 + Rules 1945 assign different functions to the central + state authorities.

• CDSCO (central, DCGI office) — New drug approval (4-year exclusivity definition under NDCT 2019), clinical-trial approval, biologicals + vaccines + ATMPs licensing, import licensing (Forms 10 / 10A / 25 / 41 / 42 / 43 etc), Class C + D medical devices, blood + blood-products central oversight, central inspections + Joint Inspections with SLAs, coordinating WHO PQ + international reliance, standards setting via IPC, drug recall + safety alerts.
• State Licensing Authorities (SLAs) — Manufacturing licences for non-new drugs (Form 25 / 28 / 28A / 28D — Schedule M-compliant manufacturing), retail + wholesale licences (Form 20 / 20A / 20B / 21 / 21A / 21B), Class A + B medical device manufacturing, state-level inspections, day-to-day enforcement, prosecution of state-level offences, retail + wholesale pharmacy oversight.
• Joint Inspections — CDSCO + SLA jointly inspect manufacturing sites for purposes including export NOC + market complaints + central-state coordination.
• Risk-based inspection harmonisation — sustained CDSCO effort to harmonise inspection standards across SLAs; differences persist + manufacturers experience variation across states.
• Schedule M — defines Good Manufacturing Practices for drugs in India; revised + updated several times (most significantly the 2023 + 2024 revisions raising alignment with WHO GMP + introducing risk-based + computerised-systems + supply-chain expectations).
• Schedule M-I (Recommended for use of Indian Pharmacopoeia) + Schedule M-III (for medical devices, now substantially superseded by the Medical Devices Rules 2017 + Schedule V).

The Medical Devices Rules 2017 + Feb 2020 amendment progressively brought ALL medical devices (previously only ~30 'notified devices' were regulated) under risk-based licensing — a transformational change for the Indian device industry + foreign manufacturers supplying India. Phased registration + licensing transitions ran through 2022-2024 with full compliance now expected.

• Class A — Lowest risk (e.g. surgical dressings, alcohol swabs).
• Class B — Low-moderate risk (e.g. hypodermic needles, suction equipment).
• Class C — Moderate-high risk (e.g. lung ventilators, bone-fixation plates).
• Class D — Highest risk (e.g. heart valves, implantable defibrillators).
• Licensing authority — Class A + B = State Licensing Authority (SLA); Class C + D = Central Licensing Authority (CDSCO).
• Manufacturing licence — Form MD-5 / MD-9 (manufacturing licence) + Form MD-3 (loan licence) + Form MD-7 (for clinical investigation); applications via SUGAM.
• Import licence — Form MD-15 (import licence for medical devices); applicant must be an Indian Authorised Agent of the foreign manufacturer + provide Plant Master File + Device Master File + Free Sale Certificate / Equivalent regulatory status.
• QMS — Schedule V of the Medical Devices Rules 2017 defines the QMS requirements, substantively aligned with ISO 13485:2016.
• Clinical Investigation — Form MD-22 (permission for clinical investigation) per the Medical Devices Rules 2017 Part X.
• Free Sale Certificate equivalence — for imported devices, the manufacturer's home regulator (FDA / EMA / Health Canada / TGA / PMDA / MHRA) Free Sale Certificate or equivalent regulatory status documentation is required.
• UDI — mandatory UDI on Class C + D devices being phased in; recognition of issuing agencies including GS1 + medical-device-specific issuing entities aligned with IMDRF + FDA + EU + AusUDI principles.
• Notified Body — for Class C + D, CDSCO may engage Notified Bodies for assessment functions per the Medical Devices Rules 2017 framework.
• IVDs — Class A / B / C / D with separate classification rules + a CDSCO IVD-specific review architecture.

• Schedule M — defines Good Manufacturing Practices for drugs in India under the Drugs and Cosmetics Rules 1945; revised multiple times historically, with the 2023 + 2024 revisions raising substantial alignment with WHO GMP + the PIC/S GMP guide, introducing risk-based quality + computerised-systems + data-integrity + supply-chain expectations + Annex-style coverage of specific dosage forms + utilities.
• Schedule M-I + M-III — historical Schedules now substantially overlaid by the modernised Schedule M + the Medical Devices Rules 2017.
• Indian Pharmacopoeia (IP) — published by IPC; the legal compendium for drugs in India; IP general chapters + monographs are mandatory; manufacturers must comply with IP specifications or have justified alternative (typically USP / EP / JP).
• CDSCO + SLA inspection programme — central inspections coordinated by CDSCO HQ + Zonal Offices; state inspections under SLAs; Joint Inspections for export NOC + complaint investigation; risk-based inspection scheduling.
• Overseas inspections — CDSCO + delegated inspectors conduct overseas inspections of foreign manufacturing sites supplying India (especially for biologicals + vaccines + new drugs).
• Data integrity — CDSCO + SLA inspectorate progressively enforcing ALCOA+ + data-integrity expectations substantively aligned with PIC/S PI 041 + WHO + MHRA expectations; recent inspections show data-integrity findings tracked + escalated.
• PIC/S applicant + observer — India is a long-standing PIC/S applicant + observer; PIC/S accession would substantially strengthen the inspectorate's international reliance position.
• Non-compliance + market action — Drug + Cosmetic Act prosecution, manufacturing-licence suspension or cancellation, import-licence suspension, product recall, criminal referral for cases of fraud / data falsification.

• Pharmacovigilance Programme of India (PvPI) — national pharmacovigilance programme coordinated by IPC + the AMC (ADR Monitoring Centre) network; the National Coordination Centre is at IPC Ghaziabad.
• VigiFlow — PvPI submission gateway; E2B-aligned ICSR format; India is a major contributor to WHO VigiBase via UMC Uppsala.
• Reporting timelines — Serious unexpected ADRs (SUSARs) within 15 calendar days of MA / applicant awareness; other categories per NDCT 2019 + CDSCO Guidance.
• Periodic Safety Update Report (PSUR) — required for new drugs + biologicals per NDCT 2019; CDSCO PSUR cycle defined.
• Risk Management Plan (RMP) — increasingly expected for new drugs + biologicals + biosimilars; CDSCO + SEC guidance progressively requires RMPs.
• Materiovigilance Programme of India (MvPI) — medical-device + IVD adverse-event monitoring programme; coordinated by IPC + the AMC network + CDSCO Medical Devices Division.
• Hemovigilance Programme of India (HvPI) — blood + blood-products adverse-event monitoring.
• Recall — recall classification + execution under CDSCO + SLA-coordinated procedures; affected products notified, distribution recovered, root cause analysis + CAPA.
• Public-facing dashboards — CDSCO + IPC publish safety alerts + drug action alerts; PvPI publishes pharmacovigilance bulletins.
• Hospital + healthcare-setting reporting — progressively encouraged for both medicines + devices through the AMC network + MvPI architecture.

• ICH observer working toward Regulatory Membership — CDSCO progressively implementing ICH guidelines through CDSCO Guidance + Schedule M + NDCT 2019.
• ICMRA — CDSCO is an active member contributing on pandemic preparedness, supply chain, generics, AI / ML.
• IMDRF — CDSCO is an active participant on UDI, SaMD, AI / ML, QMS work products.
• WHO collaboration — India NRA for vaccines reached ML3 maturity in 2017 + ML4 in 2024 for selected functions; Indian vaccine manufacturers are the largest single contributor to WHO PQ globally (vaccines including pentavalent, rotavirus, measles, OPV, IPV, HPV + many others).
• PIC/S applicant + observer — long-standing applicant; PIC/S accession would substantially strengthen reliance + reduce duplicate-inspection burden.
• Bilateral memoranda — CDSCO holds active MoUs with FDA, EMA, Health Canada, MHRA, PMDA, TGA + many others enabling information exchange + cooperation + sometimes Joint Inspections.
• Quad medicines cooperation — India + Australia + Japan + US Quad working on supply-chain resilience + regulatory cooperation.
• African + LMIC NRA cooperation — CDSCO supports African + LMIC NRA capacity-building given India's role as the 'pharmacy of the developing world'.
• Indian Pharmacopoeia + international harmonisation — IPC engages with USP + EP + JP + WHO on monograph development + harmonisation initiatives.
• Indian Quad-helix — CDSCO + IPC + NIB + AMC network represent the regulatory + pharmacopoeial + reference-laboratory + pharmacovigilance ecosystem for India.

• CDSCO vs SLA jurisdiction confusion — applications mis-routed between CDSCO central + state SLA; processing delays.
• Indian Authorised Agent not properly designated — foreign manufacturer's import licence application rejected at intake.
• Schedule M gap analysis incomplete — manufacturing site fails Joint Inspection against the 2023-2024 Schedule M revision (data integrity, computerised systems, contamination control strategy for sterile, supply-chain controls).
• Indian Pharmacopoeia (IP) compliance gaps — manufacturer uses USP / EP / JP without justified alternative; CDSCO / SLA non-compliance citation.
• NDCT 2019 timeline misjudged — clinical trial permission or new drug approval timeline delays; SEC meeting calendar managed reactively.
• Medical Devices Rules 2017 + Feb 2020 amendment transition gap — devices marketed without the appropriate Class A / B / C / D licence post-transition.
• Form MD-15 import licence Plant + Device Master File deficiencies — incomplete or out-of-date submission.
• Free Sale Certificate / equivalent regulatory status documentation gaps for imported devices.
• PvPI ICSR submission late — beyond NDCT 2019 timelines; MvPI device adverse-event reports not submitted.
• Data integrity — CDSCO + SLA inspection citations on audit trail, raw data retention, computer-system validation, batch-record review.
• Recall execution incomplete — affected distribution channels not fully addressed; CDSCO + SLA verification reveals products still in commerce.
• Joint Inspection findings unresolved → export NOC delayed or withheld.
• WHO PQ implications — Indian-manufacturer site gets a critical PQ inspection finding → cascading EU + WHO + LMIC market consequences.
• Schedule M revision-pacing — small + medium Indian manufacturers struggling to meet the 2023-2024 Schedule M revision timeline (especially data integrity + computerised systems + contamination-control strategy expectations for sterile products).
• Cosmetics Rules 2020 compliance gaps — cosmetics registration + manufacturing + import licensing transitions still incomplete for some applicants.

• Pre-submission meeting count + commitment-incorporation rate before NDA + CT-NOC submission.
• SUGAM submission cycle time per application type vs CDSCO NDCT 2019 target.
• SEC meeting attendance + commitment-track record per pipeline.
• Form MD-15 + MD-9 + MD-5 licence continuity per device line.
• Schedule M revision-compliance status per manufacturing site.
• Joint Inspection outcome trend (CDSCO + SLA) per site.
• WHO PQ inspection outcome + PIR-finding count for Indian PQ-listed sites.
• PvPI + MvPI on-time ICSR + adverse-event submission rate.
• PSUR + RMP on-time submission rate.
• Recall classification + execution + verification timeline.
• UDI implementation status per Class C + D device line.
• Indian Pharmacopoeia (IP) compliance + monograph alignment.
• Indian Authorised Agent registration freshness for foreign-manufacturer principals.
• Cosmetics Rules 2020 registration + manufacturing + import licence continuity.

V5 Ultimate runs the Schedule M + QMS + pharmacovigilance + materiovigilance evidence layer underneath every CDSCO + SLA-regulated activity. Specifically:

• Schedule M (2023-2024 revision) + Annex 11-equivalent control framework — computerised-systems lifecycle, electronic-record + electronic-signature controls, ALCOA+ data-integrity expectations aligned with CDSCO + SLA inspection + WHO PQ inspection expectations.
• CDSCO + SLA inspection readiness — full document control, training, deviation, CAPA, change control, complaint, recall + post-market surveillance evidence pre-staged for CDSCO central + state SLA + Joint Inspection requests.
• SUGAM submission packaging — application content management for Form 25 / 28 / 28D / Form 10 / 41 / 42 + Form MD-5 / MD-9 / MD-15 + CT-NOC + new-drug application content.
• Indian Authorised Agent + DAA workflows — foreign-manufacturer's Indian Authorised Agent + Drug Authorised Agent structure encoded at workspace level with role-based controls + e-sig routing.
• Medical Devices Rules 2017 + Feb 2020 amendment lifecycle — Class A / B / C / D classification, licensing route (SLA vs CDSCO), Plant + Device Master File assembly, Free Sale Certificate / equivalent regulatory status documentation.
• UDI lifecycle — Class C + D UDI implementation tracking + issuing-agency selection (GS1 + medical-device-specific) + UDI database submission.
• PvPI + MvPI wiring — adverse-event capture for medicines + devices + biologicals; SUSAR 15-day submission via VigiFlow + materiovigilance via the MvPI channel.
• PSUR + RMP — NDCT 2019-aligned periodic safety reporting + risk-management planning.
• Recall execution — CDSCO + SLA-coordinated recall classification + execution + verification.
• WHO PQ readiness for Indian manufacturers — Indian PQ-listed sites get full PIR-grade record traceability + data-integrity controls + NRA-functionality evidence linkage.
• Indian Pharmacopoeia (IP) alignment — IP specification vs USP / EP / JP cross-walk + justified-alternative documentation.
• Audit trail + e-signature — 21 CFR Part 11-equivalent + Indian IT Act 2000 (electronic-signature framework) compatible record-keeping for CDSCO + SLA + WHO PQ inspection use.
• Cosmetics Rules 2020 evidence — registration + manufacturing + import licence content management for cosmetics.